(Q37138048)

18 August 2017

1 reference

title

Current treatment of HIV/hepatitis B virus coinfection (English)

1 reference

18 August 2017

0 references

1 reference

David M Iser

1

1 reference

18 August 2017

Joseph J Sasadeusz

series ordinal

2

1 reference

18 August 2017

publication date

1 May 2008

1 reference

Journal of Gastroenterology and Hepatology

18 August 2017

published in

1 reference

18 August 2017

volume

23

1 reference

18 August 2017

issue

5

1 reference

18 August 2017

page(s)

699-706

1 reference

HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Clinical implications of HIV and hepatitis B co-infection in Asia and Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Viral hepatitis in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Hepatitis B in the HIV-coinfected patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Treatment algorithm for chronic hepatitis B in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Management of patients co-infected with hepatitis B virus and HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Hepatitis B virus and HIV coinfection: results of a survey on treatment practices and recommendations for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

The influence of HTLV-III infection on the natural history of hepatitis B virus infection in male homosexual HBsAg carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

The diagnostic value of liver biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Therapeutic advances in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Assessment of treatment efficacy in HBV infection and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Chemotherapy for hepatitis B: new treatment options necessitate reappraisal of traditional endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Recombinant alpha interferon for chronic hepatitis B in anti-HIV positive patients receiving zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Results of lamivudine trials in Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Four years of lamivudine treatment in Chinese patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Hepatitis B virus mutations associated with antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

The HBV drug entecavir - effects on HIV-1 replication and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Virologic response and resistance to adefovir in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Epidemiological characteristics and risk factors of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Randomized controlled trial of screening for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Banding ligation versus beta-blockers as primary prophylaxis in esophageal varices: systematic review of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Cancer risk among men with, or at risk of, HIV infection in southern Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2008.05382.X

10.1111/J.1440-1746.2008.05382.X

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference